Proteomic Profiling of Small-Cell Lung Cancer: A Systematic Review.
diagnostics and prognostic biomarkers
large cell neuroendocrine carcinoma
neuroendocrine tumors
proteomics
small-cell lung cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Oct 2023
16 Oct 2023
Historique:
received:
06
08
2023
revised:
24
09
2023
accepted:
27
09
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
The accurate diagnosis of small-cell lung cancer (SCLC) is crucial, as treatment strategies differ from those of other lung cancers. This systematic review aims to identify proteins differentially expressed in SCLC compared to normal lung tissue, evaluating their potential utility in diagnosing and prognosing the disease. Additionally, the study identifies proteins differentially expressed between SCLC and large cell neuroendocrine carcinoma (LCNEC), aiming to discover biomarkers distinguishing between these two subtypes of neuroendocrine lung cancers. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search was conducted across PubMed/MEDLINE, Scopus, Embase, and Web of Science databases. Studies reporting proteomics information and confirming SCLC and/or LCNEC through histopathological and/or cytopathological examination were included, while review articles, non-original articles, and studies based on animal samples or cell lines were excluded. The initial search yielded 1705 articles, and after deduplication and screening, 16 articles were deemed eligible. These studies revealed 117 unique proteins significantly differentially expressed in SCLC compared to normal lung tissue, along with 37 unique proteins differentially expressed between SCLC and LCNEC. In conclusion, this review highlights the potential of proteomics technology in identifying novel biomarkers for diagnosing SCLC, predicting its prognosis, and distinguishing it from LCNEC.
Identifiants
pubmed: 37894372
pii: cancers15205005
doi: 10.3390/cancers15205005
pmc: PMC10605593
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Proteome Res. 2011 Jan 7;10(1):269-76
pubmed: 21047053
Virchows Arch. 2022 Jul;481(1):31-39
pubmed: 35357570
PLoS One. 2019 Jun 5;14(6):e0217105
pubmed: 31166966
Front Oncol. 2020 Jul 03;10:1072
pubmed: 32719746
Pharmaceutics. 2022 Aug 17;14(8):
pubmed: 36015341
J Pharm Biomed Anal. 2021 Nov 30;206:114352
pubmed: 34509662
Thorac Cancer. 2020 Apr;11(4):888-897
pubmed: 32087605
Br J Cancer. 1994 Jun;69(6):979-85
pubmed: 8198989
Acta Pharmacol Sin. 2011 Dec;32(12):1537-42
pubmed: 22019958
J Med Libr Assoc. 2020 Apr;108(2):195-207
pubmed: 32256231
Br J Cancer. 2005 Aug 22;93(4):385-6
pubmed: 16106244
J Clin Oncol. 2021 Jan 20;39(3):238-248
pubmed: 33326253
J Natl Cancer Inst. 2010 Feb 3;102(3):152-60
pubmed: 20075367
Br J Cancer. 1987 Nov;56(5):605-10
pubmed: 3426924
J Clin Oncol. 2005 Mar 20;23(9):2020-7
pubmed: 15774793
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13150-5
pubmed: 16924104
Front Cell Dev Biol. 2021 Dec 23;9:797102
pubmed: 35004693
J Thorac Oncol. 2018 Jun;13(6):752-766
pubmed: 29454048
Clin Biochem. 2008 Nov;41(16-17):1316-25
pubmed: 18652812
Mol Med Rep. 2020 Jan;21(1):51-60
pubmed: 31746355
Oncol Rep. 2012 Dec;28(6):2233-8
pubmed: 22992788
Clin Transl Med. 2022 Sep;12(9):e1060
pubmed: 36149789
Mod Pathol. 2006 Oct;19(10):1358-68
pubmed: 16862075
Biochem J. 2001 Oct 15;359(Pt 2):255-63
pubmed: 11583571
Respirology. 2006 May;11(3):269-75
pubmed: 16635084
Nat Rev Dis Primers. 2021 Jan 14;7(1):3
pubmed: 33446664
Clin Chem Lab Med. 2005;43(4):361-9
pubmed: 15899650
Br J Cancer. 2023 Feb;128(3):443-445
pubmed: 36476656
Mol Biosyst. 2011 Apr;7(4):1167-75
pubmed: 21253648
Clin Lung Cancer. 2012 Sep;13(5):334-9
pubmed: 22424871
Adv Exp Med Biol. 1995;376:231-8
pubmed: 8597253
Oncogene. 2018 Jan 18;37(3):323-331
pubmed: 28925397
Mol Cancer Res. 2023 Jul 5;21(7):648-663
pubmed: 36961398
Clin Proteomics. 2022 Jan 7;19(1):2
pubmed: 34996345
Cancers (Basel). 2021 Aug 06;13(16):
pubmed: 34439128
Clin Transl Oncol. 2017 Jul;19(7):865-873
pubmed: 28127669
Biomedicines. 2023 Jul 13;11(7):
pubmed: 37509621
Cancer Metastasis Rev. 2007 Dec;26(3-4):503-24
pubmed: 17943411
PLoS One. 2017 Apr 27;12(4):e0176219
pubmed: 28448532
Am J Dermatopathol. 2006 Apr;28(2):99-104
pubmed: 16625069
Nat Commun. 2018 Mar 13;9(1):1048
pubmed: 29535388
J Clin Bioinforma. 2011 Sep 03;1(1):23
pubmed: 21888658
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Curr Cancer Drug Targets. 2019;19(11):919-929
pubmed: 31544692
Biochim Biophys Acta. 2014 Dec;1846(2):539-46
pubmed: 25444714
Theranostics. 2020 Aug 29;10(24):10925-10939
pubmed: 33042262
Carcinogenesis. 2012 Oct;33(10):1863-70
pubmed: 22791817
J Clin Pathol. 2005 Sep;58(9):978-80
pubmed: 16126882
BMC Med Res Methodol. 2003 Nov 10;3:25
pubmed: 14606960
Am J Cancer Res. 2020 Sep 01;10(9):2865-2877
pubmed: 33042622
Br J Cancer. 2004 Jul 5;91(1):129-40
pubmed: 15199385
Biomed Res Int. 2020 Dec 24;2020:8628695
pubmed: 33426068
Curr Proteomics. 2010 Apr 1;7(1):49-65
pubmed: 20526421
Clin Lung Cancer. 2012 Mar;13(2):115-22
pubmed: 22000695
Cancers (Basel). 2022 May 26;14(11):
pubmed: 35681609
Mol Cell Proteomics. 2014 Jan;13(1):30-48
pubmed: 24085812
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
J Thorac Oncol. 2022 Mar;17(3):362-387
pubmed: 34808341
Pathol Int. 2012 Jan;62(1):28-35
pubmed: 22192801
Anticancer Res. 2004 Mar-Apr;24(2C):1031-8
pubmed: 15154618